Business Standard

Sun Pharma's Q4 pre-tax profit down 17% at Rs 577 cr on multiple one-offs

Revenues in the US market, its largest geography, came in at $375 million down 15 per cent, though the year ago period had a high base due to a one-time contribution of specialty products

Sun Pharma promoter meets Sebi chief to clarify on whistleblower complaint
Premium

Consolidated sales came in line with estimates at Rs 8,078 crore, up 15 per cent year-on-year led by India, global specialty and rest of the world businesses

Ram Prasad Sahu Mumbai
Sun Pharmaceutical Industries reported a 17 per cent year-on-year (YoY) fall in consolidated profit before tax (PBT) to Rs 577 crore for the March quarter.
 
This was below the consensus estimate of Rs 1,361 crore, caused by multiple one-offs and lower other income. Net profit, too, saw a 37 per cent YoY fall to Rs 399.8 crore, against estimates of Rs 950-1,000 crore.
 
The one-offs pertained to an anti-trust litigation, a central excise refund, and a settlement reached by its US subsidiary Dusa Pharmaceuticals.
 
It made a provision of Rs 124 crore for the settlement of an anti-trust litigation over

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: May 27 2020 | 7:45 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com